Business Description
GSK PLC
NAICS : 325412
SIC : 2834
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
Compare
Compare
Traded in other countries / regions
GSK.Argentina
•
G1SK34.Brazil
•
GS71.Germany
•
GSK N.Mexico
•
GSK.Switzerland
•
GSK.UK
•
GSK.USA
Description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 1.35 | |||||
| Debt-to-EBITDA | 2.31 | |||||
| Interest Coverage | 9 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.63 | |||||
| Beneish M-Score | -3.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.8 | |||||
| 3-Year EBITDA Growth Rate | 4.7 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | 57.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 6.76 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -1.66 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.7 | |||||
| 9-Day RSI | 29.47 | |||||
| 14-Day RSI | 35.33 | |||||
| 6-1 Month Momentum % | 9.27 | |||||
| 12-1 Month Momentum % | 23.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.31 | |||||
| Cash Ratio | 0.17 | |||||
| Days Inventory | 170.39 | |||||
| Days Sales Outstanding | 73.6 | |||||
| Days Payable | 389.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.62 | |||||
| Dividend Payout Ratio | 0.82 | |||||
| Forward Dividend Yield % | 5.17 | |||||
| 5-Year Yield-on-Cost % | 5.62 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.79 | |||||
| Operating Margin % | 20.38 | |||||
| Net Margin % | 12.9 | |||||
| ROE % | 29.06 | |||||
| ROA % | 5.51 | |||||
| ROIC % | 9.13 | |||||
| ROC (Joel Greenblatt) % | 51.96 | |||||
| ROCE % | 11.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.83 | |||||
| Forward PE Ratio | 11.9 | |||||
| PE Ratio without NRI | 15.27 | |||||
| Shiller PE Ratio | 13.69 | |||||
| Price-to-Owner-Earnings | 8.16 | |||||
| PEG Ratio | 1.03 | |||||
| PS Ratio | 1.91 | |||||
| PB Ratio | 4.14 | |||||
| Price-to-Free-Cash-Flow | 9.07 | |||||
| Price-to-Operating-Cash-Flow | 6.44 | |||||
| EV-to-EBIT | 12.36 | |||||
| EV-to-Forward-EBIT | 11.65 | |||||
| EV-to-EBITDA | 8.73 | |||||
| EV-to-Forward-EBITDA | 9.36 | |||||
| EV-to-Revenue | 2.36 | |||||
| EV-to-Forward-Revenue | 2.95 | |||||
| EV-to-FCF | 11.18 | |||||
| Price-to-Projected-FCF | 0.86 | |||||
| Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.34 | |||||
| Earnings Yield (Greenblatt) % | 8.09 | |||||
| Forward Rate of Return (Yacktman) % | 20.19 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 35,313 | ||
| EPS (TTM) (£) | 1.124 | ||
| Beta | 0.67 | ||
| Volatility % | 16.17 | ||
| 14-Day RSI | 35.33 | ||
| 14-Day ATR (£) | 0.401197 | ||
| 20-Day SMA (£) | 17.286484 | ||
| 12-1 Month Momentum % | 23.9 | ||
| 52-Week Range (£) | 12.247757 - 27.46588 | ||
| Shares Outstanding (Mil) | 4,067.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GSK PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||